52 North wins MedTech Company of the Year
52North has been awarded the prestigious title of "MedTech Company of the Year" in the 2023 Cambridge Independent Science and Technology Awards. This recognition comes as a testament to the remarkable accomplishments and advancements made by the whole company over the past year.
One of the significant highlights for 52North has been the progress made in bringing our Neutrocheck® solution into clinical trials. Collaborating with over 100 patients, doctors, and nurses, we have taken substantial strides in our aim to revolutionise healthcare.
In addition, we have initiated several exciting partnerships with renowned institutions such as the University of Cambridge, Imperial College London, and the East of England Cancer Alliances. These collaborations demonstrate our commitment to fostering innovation and driving breakthroughs in the MedTech industry.
Further solidifying our position as a pioneering force in the field, 52North became the first-ever venture investment of Macmillan Cancer Support. This significant milestone underscores our dedication to improving cancer care and patient outcomes.
Our achievements have been recognised on a global scale this year, with 52 North being selected as a finalist among more than 1000 global applicants for the prestigious MedTech Innovator event in Boston.
52 North have been hugely successful in securing £2.5 million in funding from grants and contracts provided by esteemed organisations such as Innovate UK, the National Institute for Health and Care Research (NIHR), SBRI Healthcare, and the Accelerated Access Collaborative. We continue to foster new innovative synergies and strive to build on existing connections, as well as develop new partnerships.
As the proud recipients of the "MedTech Company of the Year" award, we continue to lead the way in advancing healthcare through innovative solutions, strategic collaborations, and unwavering dedication to improving patient outcomes.